ONTX - Onconova Therapeutics posts positive data from squamous cell carcinoma treatment trial
- Onconova Therapeutics ( NASDAQ: ONTX ) said on Tuesday a Phase 2 trial testing rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa achieved a complete response of all cancerous skin lesions following four treatment cycles.
- Both participants achieved a complete response of all cancerous skin lesions, the company said.
- Onconova plans to review initial data with regulators to gain insights on the optimal regulatory pathway for rigosertib.
- First evaluable participant has been in complete remission with no signs of metastatic disease for >18 months; the second patient has achieved a complete response, the company said .
For further details see:
Onconova Therapeutics posts positive data from squamous cell carcinoma treatment trial